Johnson & JohnsonNYSE: JNJ
Health Care · Pharmaceuticals
$228.45
-2.46%
Vol: 5.0M
Research Digest
Thursday, June 18, 2026
Johnson & Johnson boosts U.S. manufacturing investment under its $55B plan and faces CMS drug-pricing negotiation risk, while CARVYKTI posts 57% sales growth to ~$600M.
Johnson & Johnson is expanding its Vision Care operations as part of its four-year, $55 billion U.S. manufacturing investment plan, with a new target facility announced around June 15, 2026. The company's multiple myeloma cell therapy CARVYKTI posted approximately $600 million in quarterly sales, up 57.4% year-over-year, demonstrating strong oncology momentum. J&J was also named the top-ranked healthcare company on the Wall Street Journal's 2026 Best Companies for the Future list on June 12, 2026. A material risk is that J&J and Bristol-Myers Squibb face negotiation exposure under a new CMS drug pricing rule, which could pressure future revenue on key drugs. Management has guided toward $100 billion in annual revenue and double-digit growth by end of the decade, supported by TALVEY and other oncology assets.
Previous Market Intelligence
13 daysJun 17Johnson & Johnson committed over $1B to expand U.S. vision manufacturing in Jacksonville, advancing its $55B domestic buildout.Positive▶
On June 15, 2026, Johnson & Johnson announced an investment of more than $1 billion to strengthen U.S. vision-care manufacturing in Jacksonville, Florida, naming a new target within its four-year, $55 billion U.S. manufacturing expansion launched in March 2025. The move reinforces J&J's domestic supply-chain strategy amid tariff and onshoring pressures across pharma. The company also paid about $1 billion for technology aimed at one of cancer's most 'undruggable' targets and reported positive Phase 3 MajesTEC-9 data for TECVAYLI in relapsed/refractory multiple myeloma, plus new neuroscience data on CAPLYTA, SPRAVATO and seltorexant. JNJ shares have risen sharply over the past year, though the stock fell about 2.16% to $235.66 in the latest session. The bear case: ongoing Medicare Drug Price Negotiation Program developments could pressure pharma pricing, and large capital commitments raise near-term spending without immediate revenue. Analysts nonetheless flag the stock as potentially undervalued on intrinsic-value estimates.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14Johnson & Johnson expands its oncology pipeline with a $1 billion acquisition of Firefly Bio targeting hard-to-drug cancer targets.Positive▶
Johnson & Johnson agreed to acquire Firefly Bio for about $1 billion, gaining technology aimed at one of cancer's most "undruggable" targets, deepening its oncology portfolio. The move accompanies positive Phase 3 MajesTEC-9 data for TECVAYLI (teclistamab) monotherapy in relapsed or refractory multiple myeloma, showing a substantial reduction in risk of disease progression or death versus standard of care. J&J also expanded US availability of its FDA-approved TECNIS PureSee intraocular lens and was named the top healthcare company on the WSJ's 2026 Best Companies for the Future list. The stock rose about 1.07% in the latest session. Why it matters: bolt-on M&A and pivotal trial wins support the growth pipeline. The risk is investor caution on execution despite raised guidance.
May 21JNJ's investigational Ottava robotic surgery system meets primary endpoints in gastric bypass study; psoriasis pill expected to be among biggest drugs everPositive▶
Johnson & Johnson announced its investigational Ottava robotic surgery system met primary endpoints in a clinical study evaluating safety/performance in Roux-en-Y gastric bypass through 30 days post-procedure. CNBC reported May 16 that J&J's new psoriasis pill could be one of its biggest drugs ever. J&J recently received approvals including ICOTYDE in the US for moderate-to-severe plaque psoriasis and VARIPULSE Pro in Europe. The company participated in the RBC Global Healthcare Conference May 19. Q1 2026 sales grew 9.9% with management raising 2026 guidance midpoints by 30bps (to 7% sales) and 20bps (to 5.7% adj. EPS). Quarterly dividend raised 3.1% to $1.34, marking the 64th consecutive year of increases. Stock at $229.535 (+2.35%), avg PT $258.36.
May 20J&J's Ottava surgical robot hits primary endpoints in gastric-bypass trial, positioning it to challenge Intuitive Surgical as Leerink upgrades to Outperform at $265.Positive▶
Johnson & Johnson announced its investigational Ottava soft-tissue robotic surgery system met primary endpoints in its first clinical study evaluating safety and performance in Roux-en-Y gastric bypass procedures, with FDA approval expected in 2026. The milestone positions J&J to enter a robotic surgery market long dominated by Intuitive Surgical's da Vinci. On May 13, Leerink upgraded JNJ to Outperform from Market Perform with a $265 price target (up from $252). Q1 revenue of $24.06B drove raised full-year guidance to $99.7-100.7B, and the board lifted the quarterly dividend 3.1% to $1.34 (ex-date May 26), marking the 64th consecutive annual increase. J&J also closed/completed its Atraverse Medical acquisition. The new psoriasis pill is expected to be one of its biggest drugs ever. Risks remain tied to ongoing talc litigation exposure and competitive launches.
May 19Leerink upgraded J&J to Outperform on new drug momentum as the Ottava surgical robot hit its primary endpoint and Tremfya Phase 3 FUZION data reported out.Positive▶
Leerink upgraded Johnson & Johnson to Outperform on May 13, 2026, citing momentum across the pipeline. J&J announced that its investigational Ottava soft-tissue surgical robotic system met its primary endpoints in its first clinical study for Roux-en-Y gastric bypass through 30 days post-procedure, with expected approval in 2026. The company also reported Phase 3 FUZION results for Tremfya and Phase 2b data from JNJ-4804, and shared favorable IMPACT trial data for Abiomed's Impella 5.5 in high-risk cardiac surgery patients. J&J declared a $1.34 cash dividend with a May 26 ex-date and is closing the Atraverse Medical acquisition in Q2. Bear case: ongoing talcum powder litigation, biosimilar erosion of legacy biologics, and competitive pressure on Stelara/Tremfya pricing remain headwinds.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15J&J upgraded by Leerink on new drug launches as OTTAVA robotic surgery hits primary endpoints and dividend is raised 3.1%Positive▶
On May 13, Leerink Partners upgraded JNJ to Outperform from Market Perform, citing growth prospects from newly approved Icotyde and Inlexzo. On May 5, J&J announced its investigational OTTAVA Robotic Surgical System met primary safety and performance endpoints in a 30-patient gastric bypass study with all procedures completed robotically without conversion. The board raised the quarterly dividend 3.1% to $1.34 (64th consecutive annual increase), with an ex-date of May 26. The company also reported Phase 3 FUZION data for Tremfya and Phase 2b JNJ-4804 results, plus a U.S. pilot study supporting Impella 5.5 in high-risk cardiac surgery. UBS, HSBC, Guggenheim, Barclays, Stifel, Morgan Stanley, RBC and Citi raised price targets, several to $280. Shares are at $230.31 with a $238 consensus PT.
May 14JNJ rallies 2.8% on May 13 after Leerink and Johnson Rice upgrade to Outperform citing newly approved Icotyde (oral psoriasis peptide) and Inlexzo as growth re-rating drivers.Positive▶
On May 13, 2026, Leerink Partners upgraded Johnson & Johnson to Outperform from Market Perform, and Johnson Rice followed with a similar upgrade from Hold, both citing growth from newly approved products Icotyde (icotrokinra, oral plaque psoriasis peptide approved by FDA in March 2026) and Inlexzo. Shares jumped 2.8% intraday, trading as high as $230.80 and last at $230.43. Analysts forecast $405M in Icotyde sales in FY26 — 50% above consensus — and raised five-year sales growth targets by 24-34% annually. Q1 2026 EPS was $2.70 vs $2.68 consensus on $24.06B revenue (vs $23.60B est). The quarterly $1.34 dividend goes ex on May 26. Risk: the re-rating thesis depends on continued strong uptake of new launches; underlying base businesses still face biosimilar headwinds, and the consensus is only catching up to a stock that has already rallied 43% over 12 months.
May 13J&J announced positive pivotal OTTAVA robotic surgical system clinical results May 5 (30 of 30 procedures completed without conversion) with 2026 approval expected; presenting at BofA healthcare conference May 12 and RBC May 19.Positive▶
Johnson & Johnson announced May 5 the first clinical study results for its investigational OTTAVA Robotic Surgical System in Roux-en-Y gastric bypass procedures, with all 30 patients completed robotically without conversion and primary safety/performance endpoints met at 30 days; J&J expects FDA approval in 2026. On May 7 the company launched the "Generation Fine" global depression-care campaign. JNJ presented at the BofA Global Healthcare Conference May 12 (John Reed, EVP Innovative Medicine and R&D), and will present at the RBC Global Healthcare Conference May 19. The company will present 18 abstracts of neuropsychiatry data at the APA Annual Meeting (May 16-20) and ASCP (May 26-29). Shares trade at $222-227 with a $536B market cap and a $1.34 dividend ex-date May 26. Q1 saw the FDA approval of Icotyde (Icotrokinra) for plaque psoriasis (a first-in-class oral peptide).
May 12J&J's OTTAVA robotic surgical system met primary safety/performance endpoints in its first clinical study of Roux-en-Y gastric bypass procedures, with approval expected in 2026; shares trade ~$222.51.Positive▶
On May 5, J&J announced positive 30-day results from the first clinical study of its investigational OTTAVA Robotic Surgical System in gastric bypass, with all procedures completed robotically without conversion - approval is targeted for 2026. On May 11, the company disclosed 18 abstracts from its neuropsychiatry portfolio for presentation at the APA (May 16-20) and ASCP (May 26-29) meetings. New IMPACT pilot data supported the Abiomed Impella 5.5 system in high-risk cardiac surgery patients. JNJ declared a $1.34 dividend (ex-date May 26). Stock is up ~43% over the past year, trading at a P/E of 25.5x vs. a 3-year average of 20.6x, with revenue growth of 7.9% LTM.
May 11J&J's investigational Ottava soft-tissue surgical robot met its primary endpoints in a pivotal study reported May 5, positioning the company to challenge Intuitive Surgical's da Vinci, while an IBD therapy missed its primary endpoint the same day.Mixed▶
On May 5, J&J announced its Ottava robotic surgery system met primary endpoints in its first pivotal study (safety/performance in Roux-en-Y gastric bypass through 30 days post-procedure), with management expecting approval sometime in 2026 - a key entry into the robotic surgery market historically dominated by Intuitive Surgical. Separately, J&J's closely watched IBD therapy failed to show statistically meaningful improvement in its trial reported May 5, though the company plans to advance the drug into late-stage testing in a defined subgroup. J&J also released positive cardiac surgery data from its Abiomed Impella 5.5 IMPACT pilot study, and launched a global depression-awareness campaign called Generation Fine. The board declared a 3.1% dividend increase to $1.34/share (64th consecutive year of increases), ex-date May 26. Shares trade around $222 with market cap ~$536B. Key risk: 2026 guidance already absorbs hundreds of millions of dollars of Trump-administration drug pricing impact plus the CVS Stelara formulary drop.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $1,095.88 | -1.45% | +8.9% | 25.0x | 0.52 | $991.6B |
| JNJJOHNSON | $228.45 | -2.46% | +1.8% | 18.4x | 0.26 | $563.8B |
| MRKMERCK | $112.50 | -2.55% | +1.1% | 12.1x | 0.22 | $285.1B |
| PFEPFIZER | $25.10 | -3.18% | +1.0% | 9.2x | 0.29 | $147.7B |
| BMYBRISTOL | $53.78 | -2.72% | -5.2% | 9.0x | 0.24 | $112.9B |
| ZTSZOETIS | $77.70 | +0.57% | -2.1% | 10.4x | 0.74 | $32.4B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.